Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 3OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 181Lymphoma 97Lymphoma, Large B-Cell, Diffuse 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Sarcoma 69Hodgkin Disease 54Lymphoma, Non-Hodgkin 41Triple Negative Breast Neoplasms 37Burkitt Lymphoma 36Lymphoma, Mantle-Cell 32Leukemia 32Lymphoma, Follicular 30Multiple Myeloma 28Carcinoma, Hepatocellular 28Neoplasm Metastasis 23Ovarian Neoplasms 21Neoplasms 21Lymphoma, Large-Cell, Anaplastic 18Osteosarcoma 17Lymphoma, B-Cell 17Prostatic Neoplasms 16Neuroblastoma 15Lymphoma, T-Cell, Peripheral 15Urinary Bladder Neoplasms 14Recurrence 13Lymphoma, Large-Cell, Immunoblastic 13Inflammatory Breast Neoplasms 13Immunoblastic Lymphadenopathy 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Stomach Neoplasms 10

Interventions

Rituximab 5fludarabine 4Tacrolimus 4Epoetin Alfa 4Cyclophosphamide 4Busulfan 4Darbepoetin alfa 3Alemtuzumab 3fludarabine phosphate 2entrectinib 2atezolizumab 2alectinib 2Thiotepa 2Therapeutics 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Etoposide 2Early Intervention, Educational 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1trametinib 1tirbanibulin 1sargramostim 1plerixafor 1phenethyl isothiocyanate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoproliferative Disorders × Doxorubicin × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡